NGS data could be used to confirm HER2 amplification in HER2-positive invasive breast carcinomas with positive HER2 IHC results and to reveal HER2 amplification in HER2-positive invasive breast carcinomas with negative HER2 IHC results. Here, ERBB2 is linked to invasive breast carcinoma.